The Vioxx Recall Tested Our Leadership
Harvard Business Review
OCTOBER 6, 2011
They said that it might be possible to go to the FDA, add warnings to the label, and keep Vioxx on the market, but they believed that the most responsible course of action in the interests of the patient was to voluntarily withdraw the drug. We had done a restructuring in 2001 with a significant number of layoffs. billion in revenues.
Let's personalize your content